English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Vincristine is an effective chemotherapeutic drug for various cancers, including acute lymphoblastic leukemia ( ALL ). Unfortunately, clinical utility is restricted by dose‐limiting vincristine‐induced peripheral neuropathies ( VIPN ). We sought to determine the association of  VIPN  with a recently identified risk variant,   CEP 72  rs924607, and drug absorption, distribution, metabolism, and excretion ( ADME ) gene variants in pediatric  ALL . This was followed by a meta‐analysis of pharmacogenomic data from over 500 patients.   CEP 72  rs924607 was significantly associated with  VIPN  ( P  =   0.02; odds ratio ( OR ) = 3.4).  ADME  analyses identified associations between  VIPN  and   ABCC 1  rs3784867 ( P  =   5.34 × 10 −5 ;  OR  = 4.9), and   SLC 5A7  rs1013940 ( P  =   9.00 × 10 −4 ;  OR = 8.6); genes involved in vincristine transport and inherited neuropathies, respectively. Meta‐analysis identified an association with a variant related to   TTPA   (rs10504361:  P  =   6.85 × 10 −4 ;  OR  = 2.0), a heritable neuropathy‐related gene. This study provides essential corroboratory evidence for   CEP 72  rs924607 and highlights the importance of drug transporter and inherited neuropathy genes in  VIPN .

Pharmacogenomics of Vincristine‐Induced Peripheral Neuropathy Implicates Pharmacokinetic and Inherited Neuropathy Genes